PACB Earnings Date: Nov 3, 2026 (Estimated) — Pacific Biosciences of California, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is PACB's next earnings date?
Pacific Biosciences of California, Inc. (PACB) is expected to report earnings on Tuesday, November 3, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.13 on revenue of $43.8M.
How did PACB do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Pacific Biosciences of California, Inc. posted EPS of -$0.14 versus the -$0.13 estimate, a miss of 7.7%. Revenue was $39.0M against a $41.0M estimate. The stock's 1-day post-earnings move was -10.4%.
How much does PACB stock move after earnings?
PACB beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.3% (up or down) in the day after earnings.
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.13 | -0.14 | -7.69% | $39.0M | ❌ Miss | -10.38% | -14.62% | +0.00% |
| 2026-08-03 | -0.13 | -0.14 | -9.38% | $39.0M | ❌ Miss | +2.86% | -15.36% | -3.21% | |
| 2026-05-07 | Q1 2026 | -0.14 | -0.12 | +14.29% | $37.2M | ✅ Beat | -14.55% | -26.67% | -16.36% |
| 2026-02-12 | Q4 2025 | -0.16 | -0.12 | +25.00% | $44.6M | ✅ Beat | -7.07% | -12.50% | -26.09% |
| 2025-11-05 | Q3 2025 | -0.15 | -0.12 | +20.00% | $38.4M | ✅ Beat | -7.05% | -9.14% | +24.80% |
| 2025-02-13 | Q4 2024 | -0.21 | -0.20 | +4.76% | $39.2M | ✅ Beat | +25.00% | +4.05% | -16.22% |
| 2024-11-07 | Q3 2024 | -0.22 | -0.17 | +22.73% | $40.0M | ✅ Beat | -6.12% | -24.29% | -11.02% |
| 2024-08-07 | Q2 2024 | -0.23 | -0.20 | +13.04% | $36.0M | ✅ Beat | +9.15% | -11.76% | +3.27% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $72.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 45.8% | $33.0M | -0.4% | $65.8M | $31.1M | $33.1M | $32.6M |
| Consumable | 27.9% | $20.1M | +6.2% | $35.9M | $20.1M | $18.9M | $21.3M |
| Instrument | 17.8% | $12.8M | -9.3% | $30.0M | $11.0M | $14.2M | $11.3M |
| Service And Other | 8.4% | $6.1M | -9.4% | $9.4M | $6.0M | $6.7M | $5.8M |
By region
Q2 FY26 · $39.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Americas | 45.2% | $17.6M | -0.4% | $40.9M | $16.3M | $17.7M | $18.1M |
| EMEA | 37.0% | $14.4M | +52.4% | $17.1M | $9.2M | $9.5M | $10.8M |
| Asia Pacific | 17.8% | $7.0M | -44.8% | $17.2M | $11.6M | $12.6M | $9.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.